Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 SubvariantBusiness Wire • 05/19/22
FDA Lifts Clinical Hold on Immunome's IMM-BCP-01 IND Application for the Treatment of COVID-19Business Wire • 03/11/22
Immunome Shares Seesaw After COVID-19 Antibody Cocktail Works Against Live Omicron VirusBenzinga • 02/08/22
Immunome's Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus TestingBusiness Wire • 02/08/22
Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19Business Wire • 01/10/22
Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron VariantBusiness Wire • 12/01/21
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19Business Wire • 11/29/21
Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and ProphylaxisBusiness Wire • 10/20/21
Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBusiness Wire • 10/07/21
Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBusiness Wire • 09/30/21
Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech SummitBusiness Wire • 09/15/21